Unknown

Dataset Information

0

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease.


ABSTRACT:

Background

The prognostic factors of morbidity and mortality in patients with lean NAFLD (body mass index < 25.0 kg/m2) are unknown.

Methods

In this retrospective study, 446 Japanese patients with histopathologically-confirmed NAFLD (lean NAFLD, n = 170) were followed for liver events, cardiovascular events, type 2 diabetes mellitus, and non-liver malignancies. The median observation period was 4.6 years. We also investigated the predictors of severe fibrosis (stage 3-4) and mortality in lean NAFLD patients.

Results

Glycolipid metabolic markers, liver function tests, NAFLD fibrosis score (NFS), and histological scoring were significantly lower in lean NAFLD patients than in non-lean NAFLD. The incidence of liver cancer was higher while that of T2DM was lower in lean NAFLD. Kaplan-Meier analysis showed no significant difference in overall survival between the lean and non-lean NAFLD. Multivariate analysis of data of lean NAFLD identified NFS ≥ - 1.455 as significant independent predictor of severe fibrosis, while history of liver cancer and NFS ≥ - 1.455 were predictors of overall survival.

Conclusions

Although patients with lean NAFLD have better histopathological and biochemical profile compared to patients with non-lean NAFLD, the prognosis is not different between the two groups. Lean NAFLD patients with NFS ≥ - 1.455 or history of liver cancer should be monitored carefully during follow-up.

SUBMITTER: Iritani S 

PROVIDER: S-EPMC7640447 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>The prognostic factors of morbidity and mortality in patients with lean NAFLD (body mass index < 25.0 kg/m<sup>2</sup>) are unknown.<h4>Methods</h4>In this retrospective study, 446 Japanese patients with histopathologically-confirmed NAFLD (lean NAFLD, n = 170) were followed for liver events, cardiovascular events, type 2 diabetes mellitus, and non-liver malignancies. The median observation period was 4.6 years. We also investigated the predictors of severe fibrosis (stage 3-4  ...[more]

Similar Datasets

| S-EPMC7028415 | biostudies-literature
| S-EPMC7673972 | biostudies-literature
| S-EPMC10327437 | biostudies-literature
| S-EPMC7137333 | biostudies-literature
| S-EPMC7665822 | biostudies-literature
| S-EPMC8170238 | biostudies-literature
| S-EPMC10436134 | biostudies-literature
| S-EPMC8924809 | biostudies-literature
| S-EPMC8468081 | biostudies-literature
| S-EPMC9830772 | biostudies-literature